Allenex AB (publ) announced on 20 May 2016 that the company had decided to apply for de-listing of the Allenex share from Nasdaq Stockholm. The application has now been approved.

The last day of trading in the Allenex share will be Wednesday 8 June 2016.

For more information please contact: 
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail: 

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on May 25, 2016, at 08.00 CET.  Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 57 persons are employed in the Allenex group. 


About Us

LinkMed, in collaboration with innovators, develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED). The company’s largest owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. See for more information.

Documents & Links